Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib in Hypercholesterolemia or Low HDL-C
NCT01860729Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Anacetrapib with Placebo (2 arms). Primary endpoints: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol at 24 weeks, Percent Change from Baseline in High-Density Lipoprotein Cholesterol at 24 weeks and 5 more. Started May 2013; status: completed.
02
Drugs
anacetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01860729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860729.